JMP Securities raised the firm’s price target on Crispr Therapeutics to $80 from $74 and keeps an Outperform rating on the shares. The approval of both sickle cell disease cell therapies by the FDA removes some immediate binary risk, and Friday’s price decline of down 8% is trading related, not fundamental, the analyst tells investors in a research note. JMP views Crispr’s Casgevy as best in class and believes the label reflects key benefits.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRSP:
- Vertex (NASDAQ:VRTX), CRISPR Therapeutics Slip despite Sickle Cell Treatment Approval
- Crispr says Casgevy approval triggers $200M milestone payment
- Vertex sets $2.2M as U.S. wholesale acquisition cost for Casgevy
- Vertex and Crispr announce FDA approval of Casgevy for sickle cell disease
- Mizuho sees black box warning just for Bluebird, not Crispr